Who are the top shareholders of the Suven Life Scie.?

The top shareholders of Suven Life Sciences include Jasti Property And Equity Holdings Private Limited with 69.56%, individual investors with 24.04%, and foreign institutional investors holding 0.25%. There are no pledged promoter holdings or significant public shareholders.

The top shareholders of Suven Life Sciences primarily include the promoters, with Jasti Property And Equity Holdings Private Limited being the largest shareholder, holding 69.56% of the company. There are also individual investors who collectively own 24.04% of the shares. Additionally, mutual funds hold a very small percentage (0.01%) across three schemes, and foreign institutional investors (FIIs) have a combined holding of 0.25% through 14 different entities. There are no pledged promoter holdings or significant public shareholders noted.

What is the bonus history of the Suven Life Scie.?

Suven Life Sciences Ltd has a bonus history that includes a 1:1 bonus issue announced on March 23, 2007, with a record date of April 2, 2007, allowing shareholders to receive an additional share for each share held.

Suven Life Sciences Ltd has a bonus history that includes a 1:1 bonus issue. This was announced with an ex-date of March 23, 2007, and the record date for this bonus was April 2, 2007. This means that shareholders on record as of the record date received an additional share for every share they held.

Has Suven Life Scie. declared dividend?

Yes, Suven Life Sciences Ltd has declared a dividend of 150% (₹1.5 per share) with an ex-date of February 14, 2019. However, the dividend yield is 0%, indicating that returns are mainly from price appreciation rather than dividend income.

Suven Life Sciences Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 150%<BR>- Amount per share: 1.5<BR>- Ex-date: 14 Feb 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 47.35%, the dividend return was 0%, resulting in a total return of 47.35%.<BR><BR>For the 1-year period, the price return was 135.02%, the dividend return was 0%, leading to a total return of 135.02%.<BR><BR>Over the 2-year period, the price return was 267.93%, with a dividend return of 0%, culminating in a total return of 267.93%.<BR><BR>In the 3-year period, the price return was 176.98%, the dividend return was 0%, which resulted in a total return of 176.98%.<BR><BR>For the 4-year period, the price return was 133.95%, the dividend return was 0%, giving a total return of 133.95%.<BR><BR>In the 5-year period, the price return was 516.17%, with a dividend return of 0%, resulting in a total return of 516.17%.<BR><BR>Overall, while Suven Life Sciences Ltd has declared a significant dividend, the dividend yield remains at 0%, indicating that the returns are primarily driven by price appreciation rather than dividend income. The total returns over various periods show strong performance, particularly over the longer term.

Who are the peers of the Suven Life Scie.?

Suven Life Sciences' peers include Syngene Intl., Dr Lal Pathlabs, and Poly Medicure, among others. Suven Life Sciences has the highest 1-year return at 160.99%, while it has below-average management risk and capital structure compared to its peers.

Peers: The peers of Suven Life Scie. are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Vimta Labs, Laxmi Dental, Krsnaa Diagnost., Tarsons Products, and Suraksha Diagno.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and the rest. Average management risk is present at Vimta Labs and Krsnaa Diagnost., while Below Average management risk is noted for Suven Life Scie. and Tarsons Products. Growth is Excellent at Vimta Labs and Laxmi Dental, Average at Poly Medicure and Indegene, and Below Average at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Suven Life Scie., Krsnaa Diagnost., and Tarsons Products. Capital Structure is Excellent at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and Krsnaa Diagnost., Good at Laxmi Dental and Tarsons Products, and Below Average at Suven Life Scie.<BR><BR>Return Snapshot: Suven Life Scie. has the highest 1-year return at 160.99%, while Syngene Intl. has the lowest at -3.51%. Compared to its peers, Suven Life Scie. significantly outperforms them in 1-year returns. Additionally, Krsnaa Diagnost. and Tarsons Products have negative six-month returns.

Is Suven Life Scie. overvalued or undervalued?

As of October 14, 2020, Suven Life Sciences is considered overvalued and risky due to negative financial ratios, including a PE ratio of -30.02 and an EV to EBITDA of -28.75, despite a strong historical return of 128.61% over the past year.

As of 14 October 2020, the valuation grade for Suven Life Sciences moved from expensive to risky. The company is currently considered overvalued based on its financial ratios, which include a PE ratio of -30.02, an EV to EBITDA of -28.75, and a ROCE of -343.32%. These figures indicate significant financial distress and a lack of profitability, which is concerning for potential investors.<BR><BR>In comparison to its peers, Suven Life Sciences stands out negatively; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE of 22.99 and an EV to EBITDA of 15.93. These comparisons highlight that Suven Life Sciences is not only underperforming but also carries a much higher risk profile. Despite a strong historical performance with a 1Y return of 128.61% compared to the Sensex's 7.61%, the current valuation metrics suggest that the stock is overvalued and may not be a prudent investment at this time.

Who are in the management team of Suven Life Scie.?

As of March 2023, the management team of Suven Life Sciences includes Venkateswarlu Jasti (Chairman & CEO), Sudha Rani Jasti (Whole-time Director), Seyed E Hasnain (Director), and several Independent Directors: M Gopalakrishna, Santanu Mukherjee, J A S Padmaja, along with Shrenik Soni (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

As of March 2023, the management team of Suven Life Sciences includes:<BR><BR>1. Venkateswarlu Jasti - Chairman & CEO<BR>2. Sudha Rani Jasti - Whole-time Director<BR>3. Seyed E Hasnain - Director<BR>4. M Gopalakrishna - Independent Director<BR>5. Santanu Mukherjee - Independent Director<BR>6. J A S Padmaja - Independent Director<BR>7. Shrenik Soni - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Suven Life Scie. do?

Suven Life Sciences Ltd is a mid-cap healthcare services company, incorporated in 1989, with recent net sales of 15 Cr and a net profit of -439 Cr as of March 2025. The company focuses on pharmaceutical development and has a market cap of INR 6,329 Cr.

Overview:<BR>Suven Life Sciences Ltd operates in the healthcare services industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was incorporated in March 1989 and changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September 2003. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 15 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -439 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 6,329 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.55 <BR>Return on Equity: -146.14% <BR>Price to Book: 58.69<BR><BR>Contact Details:<BR>Address: #8-2-334 SDE Serene Chambers, 6 th Floor Road No 5 Avenue 7 Hyderabad Telangana : 500034 <BR>Tel: 91-40-23541142/3311/3315 <BR>Email: info@suven.com <BR>Website: http://www.suven.com

How big is Suven Life Scie.?

As of 24th July, Suven Life Sciences Ltd has a market capitalization of 6,158.00 Cr, with Net Sales of 6.66 Cr and a Net Profit loss of 160.74 Cr over the latest 4 quarters. Shareholder's Funds are 270.04 Cr, and Total Assets are valued at 284.90 Cr.

As of 24th July, Suven Life Sciences Ltd has a market capitalization of 6,158.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 6.66 Cr. However, it faced a loss of 160.74 Cr in Net Profit during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2024. Shareholder's Funds stand at 270.04 Cr, while Total Assets are valued at 284.90 Cr.

When is the next results date for Suven Life Scie.?

Suven Life Sciences will announce its results on 11 November 2025.

Suven Life Sciences will declare its results on 11 November 2025.

Are Suven Life Scie. latest results good or bad?

Suven Life Sciences' latest results are concerning, showing a net loss of ₹51.52 crores in Q2 FY26, a significant increase from the previous year, despite an 85.15% revenue growth to ₹1.87 crores. The company's severe operational challenges and high costs indicate a troubling financial situation with no clear path to profitability.

Suven Life Sciences' latest results are concerning. In Q2 FY26, the company reported a net loss of ₹51.52 crores, which is an increase of 83.74% year-on-year, indicating a worsening financial situation. While revenue showed a significant year-on-year growth of 85.15%, reaching ₹1.87 crores, this figure remains alarmingly low and insufficient to cover the company's operational expenses.<BR><BR>The operating margin was reported at an extremely negative -2713.37%, reflecting a severe inability to manage costs relative to revenue. Additionally, the profit after tax (PAT) margin was also deeply negative at -2755.08%. The company has been struggling with a high cost structure, particularly with employee costs that far exceed revenue, leading to significant operational losses.<BR><BR>Overall, the financial performance indicates that Suven Life Sciences is facing critical operational challenges, with no clear path to profitability in sight. The combination of persistent losses, unsustainable costs, and a weak revenue base suggests that the latest results are quite bad for the company.

How has been the historical performance of Suven Life Scie.?

Suven Life Sciences has experienced a significant decline in financial performance, with net sales dropping from 285.67 crore in March 2019 to 6.66 crore in March 2025, and increasing losses leading to a net profit of -160.75 crore in March 2025. The company faces ongoing operational challenges, reflected in negative cash flow and reduced asset values.

Answer:<BR>The historical performance of Suven Life Sciences has shown a significant decline in key financial metrics over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Suven Life Sciences reported net sales of 6.66 crore in March 2025, a sharp decrease from 11.69 crore in March 2024 and 13.54 crore in March 2023, continuing a downward trend from 285.67 crore in March 2019. The total operating income mirrored this decline, dropping to 6.66 crore in March 2025 from 11.69 crore in the previous year. The company's total expenditure, excluding depreciation, rose to 172.43 crore in March 2025, up from 139.70 crore in March 2024, leading to an operating profit (PBDIT) of -165.77 crore in March 2025, worsening from -128.01 crore in March 2024. Consequently, the profit before tax also deteriorated to -160.75 crore in March 2025, compared to -106.08 crore in March 2024. The net profit for March 2025 was reported at -160.75 crore, a decline from -105.08 crore in March 2024. The company's total assets decreased to 135.18 crore in March 2025 from 284.90 crore in March 2024, while total liabilities also fell to 135.18 crore from 284.90 crore in the same period. Cash flow from operating activities remained negative at -154.00 crore in March 2025, indicating ongoing operational challenges. Overall, Suven Life Sciences has faced significant financial difficulties, reflected in declining sales, increasing losses, and reduced asset values over the years.

Should I buy, sell or hold Suven Life Scie.?

Is Suven Life Scie. technically bullish or bearish?

As of December 3, 2025, the technical trend has shifted to mildly bearish, indicated by bearish signals from the weekly MACD and KST, daily moving averages, and Bollinger Bands, despite a bullish weekly RSI and strong year-to-date performance.

As of 3 December 2025, the technical trend has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish signals, while the daily moving averages confirm a bearish outlook. The weekly RSI remains bullish, but the overall technical indicators suggest a weakening trend. The Bollinger Bands show a mildly bearish signal on the weekly timeframe, further supporting the bearish stance. Despite a strong performance year-to-date and over longer periods, the recent trend shift indicates caution in the near term.

Which are the latest news on Suven Life Scie.?

Why is Suven Life Scie. falling/rising?

As of 13-Dec, Suven Life Sciences Ltd's stock price has risen to 170.95, reflecting a 1.48% increase due to positive market sentiment and increased investor participation, particularly from institutional investors. However, the company faces significant challenges, including declining net sales and operating losses, raising concerns about its long-term financial health.

As of 13-Dec, Suven Life Sciences Ltd is experiencing a rise in its stock price, currently at 170.95, reflecting a change of 2.5 (1.48%) upwards. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.43% today, indicating positive market sentiment. Additionally, there has been a notable rise in investor participation, with delivery volume increasing by 16.02% against the 5-day average, suggesting heightened interest among investors.<BR><BR>Institutional investors have also increased their stake in the company by 0.59% over the previous quarter, now holding 4.56% of the company. Their involvement typically indicates a level of confidence in the company's potential, as these investors often have more resources to analyze the fundamentals than retail investors. Furthermore, the stock has shown consistent returns over the last three years, generating a 14.77% return in the past year and outperforming the BSE500 in each of the last three annual periods.<BR><BR>However, it is important to note that the company is facing significant challenges, including operating losses and weak long-term fundamental strength, with net sales declining at an annual rate of -23.11% and operating profit at -186.11% over the last five years. The company has also reported negative results for the last five consecutive quarters, which raises concerns about its financial health.<BR><BR>Despite these negative factors, the current rise in stock price can be attributed to positive short-term performance metrics and increased investor interest, particularly from institutional investors.